Comparative Pharmacology
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus SEPTOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus SEPTOCAINE.
LARYNGOTRACHEAL ANESTHESIA KIT vs SEPTOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
Articaine is a local anesthetic of the amide type that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse conduction.
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
SEPTOCAINE (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) dental infiltration or nerve block: 0.5–1.7 mL (20–68 mg articaine) per injection site; maximum adult dose: 7 mg/kg (up to 500 mg total).
None Documented
None Documented
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
Terminal elimination half-life in adults is 2-4 hours. In neonates, it may be prolonged to 8-12 hours due to immature hepatic function.
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic